What is the Pfizer PE ratio today?
Pfizer's PE ratio is 23.4 at the 29 October 2026 close (₹3,759.80 a share): a market capitalisation of ₹17,201 crore divided by consolidated net profit of ₹735 crore over the last four quarters (Q2 FY26 to Q1 FY27). On FY26 net profit (₹722 crore) it is 23.8.
What is the Pfizer PB ratio (price to book value)?
Pfizer's price-to-book (PB) ratio is 4.09 at the 29 October 2026 close: a market capitalisation of ₹17,201 crore divided by shareholders' equity (book value) of ₹4,203 crore on 31 March 2026. That is a book value of ₹918.67 per share against a share price of ₹3,759.80.
What is the Pfizer net worth?
Pfizer's net worth — shareholders' equity in its consolidated balance sheet — was ₹4,203 crore on 31 March 2026, down 0.3% from ₹4,217 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹17,201 crore at the 29 October 2026 close.
What is the Pfizer market cap?
Pfizer's market capitalisation was ₹17,201 crore at the 29 October 2026 close: 4.58 crore shares at ₹3,759.80 each.
Is Pfizer debt free?
No. Pfizer had borrowings of ₹2.5 crore on 31 March 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.00. Its cash and current investments were ₹3,111 crore, so it held net cash of ₹3,108 crore.
What is the Pfizer dividend in 2026 and its record date?
In 2026, Pfizer has declared one dividend: ₹75 with record date 17 July 2026.
What is the Pfizer debt to equity ratio?
Pfizer's debt-to-equity ratio was 0.00 on 31 March 2026: borrowings of ₹2.5 crore against total equity of ₹4,203 crore. A year earlier, on 31 March 2025, it was 0.00.
What is the Pfizer book value per share?
Pfizer's book value per share was ₹918.67 on 31 March 2026: shareholders' equity of ₹4,203 crore divided by the 4.58 crore shares in issue. The share price at the 29 October 2026 close was ₹3,759.80.
What is the Pfizer dividend yield?
Pfizer's dividend yield is 1.99% at the 29 October 2026 close: dividends of ₹75 a share that went ex-dividend in the 12 months before that day, divided by the share price of ₹3,759.80. They were ₹75 on 17 July 2026.
What is the Pfizer ROE and ROCE?
In FY26, Pfizer's return on equity (ROE) was 17.2% and its return on capital employed (ROCE) was 19.6%. ROE is net profit divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was 19.7% and ROCE 16.9%.
What is the Pfizer shareholding pattern?
On 30 September 2026, Pfizer's shares were held by promoters 63.92%, foreign portfolio investors (FII/FPI) 1.63%, domestic institutions (DII) 17.52% (including mutual funds at 12.83%) and retail and other non-institutional investors 16.92%. Over the year, FII holding was down 0.97 percentage points from 2.60% and DII holding was up 0.42 percentage points from 17.10%.
What is the Pfizer revenue and profit in FY26?
In FY26 (April 2025–March 2026), Pfizer's consolidated net profit was ₹722 crore, down 5.9% from ₹768 crore in FY25, on revenue from operations of ₹2,520 crore (up 10.4%). Over three years, from FY23, net profit was up 15.8%.
What is the Pfizer promoter holding?
Promoters held 63.92% of Pfizer on 30 September 2026, unchanged from both the previous quarter and a year earlier, according to the shareholding pattern filed with NSE.
What is the Pfizer free cash flow?
In FY26, Pfizer generated ₹968 crore of cash from operations and spent ₹25.2 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of ₹942 crore. In FY25 it was ₹632 crore.
What are the Pfizer latest quarterly results?
Pfizer's latest results are for Q1 FY27 (April–June 2026), filed on 28 July 2026: consolidated net profit ₹204 crore, up 6.6% from ₹192 crore in Q1 FY26; revenue from operations ₹653 crore, up 8.3% year on year.
When are the Pfizer next results?
Pfizer will announce its Q2 FY27 results (July–September 2026) on Tuesday, 3 November 2026, the date of the board meeting it has notified to the exchanges.
How does Pfizer compare with its peers?
On FY26 consolidated figures, against Glaxosmithkline Pharmaceuticals, Abbott India and Poly Medicure: Pfizer's operating margin of 33.6% is the highest of the four (Glaxosmithkline Pharmaceuticals 32.5%, Abbott India 26.2%, Poly Medicure 17.4%; peer average 25.4%); its return on equity of 17.2% is the third highest of the four (Glaxosmithkline Pharmaceuticals 49.1%, Abbott India 34.5%, Poly Medicure 11.0%; peer average 31.5%); its revenue growth over three years of 1.3% a year is the lowest of the four (Glaxosmithkline Pharmaceuticals 5.5% a year, Abbott India 9.0% a year, Poly Medicure 18.9% a year; peer average 11.2% a year).
Pfizer vs Glaxosmithkline Pharmaceuticals: how do they compare?
In FY26, Pfizer earned net profit of ₹722 crore on revenue of ₹2,520 crore, against ₹1,036 crore on ₹3,822 crore for Glaxosmithkline Pharmaceuticals. Pfizer's operating margin was 33.6% (Glaxosmithkline Pharmaceuticals 32.5%) and its return on equity 17.2% (Glaxosmithkline Pharmaceuticals 49.1%). At the 29 October 2026 close, Pfizer's market capitalisation was ₹17,201 crore against ₹42,608 crore for Glaxosmithkline Pharmaceuticals, and its PE ratio on FY26 profit 23.8 against 41.1.
Consolidated figures from the company's filings with NSE; prices are NSE closing prices.
